ArticleFrontiers in oncology2025
The role of PSMC4 in non-small cell lung cancer: implications for prognosis, diagnosis, and immune microenvironment modulation.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Non-small cell lung cancer (NSCLC) remains a principal cause of cancer-related mortality. The discovery of novel biomarkers is pivotal for enhancing early diagnosis, refining prognostic evaluations, and optimizing targeted therapeutic strategies. Proteasome 26S subunit ATPase 4 (PSMC4), a proteasome subunit essential for protein degradation, influences tumor progression regulatory mechanisms. Despite its recognized importance, the specific contributions of PSMC4 to NSCLC progression are not well defined. Methods: This investigation employs a combination of bioinformatics and histological methods to delineate the expression profile of PSMC4 in NSCLC and its correlations with clinicopathological characteristics, diagnostic efficacy, prognostic value, and tumor microenvironment. Results: We reveal an elevated level of PSMC4 in various malignancies, notably lung adenocarcinoma. Elevated levels of PSMC4 are strongly associated with higher pathological T stages, N stages, and pathological stages. Analysis using receiver operating characteristic curves demonstrates the high diagnostic sensitivity and specificity of PSMC4. Furthermore, patients with elevated PSMC4 levels experience markedly reduced overall survival, disease-specific survival, and progression-free intervals. Both univariate and multivariate Cox regression analyses substantiate that PSMC4 serves as an independent prognostic marker. Analysis of differentially expressed genes and functional annotation demonstrate that genes related to PSMC4 are crucial across a spectrum of biological processes, including DNA replication, chromatin assembly, and mitotic prophase. Gene set enrichment analysis reveals significant correlations between PSMC4 and essential signaling pathways such as the G2/M DNA damage checkpoint, WNT signaling pathway, and cellular senescence. Moreover, immunohistochemical evaluations confirm the increased expression of PSMC4 in NSCLC tissues. Functional assays reveal that PSMC4 accelerates the proliferation of lung cancer cells and tumor growth in xenograft models. Discussion: These results highlight the potential of PSMC4 as a diagnostic and prognostic marker in NSCLC and elucidate its integral role within the tumor immune microenvironment. Consequently, targeting PSMC4 emerges as a viable therapeutic approach for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.